A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Hepatitis B; Hepatitis C; Liver cancer
- Focus Adverse reactions
- Sponsors MedImmune
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Planned End Date changed from 16 Apr 2018 to 21 Dec 2018.
- 07 Jun 2017 Planned primary completion date changed from 16 Apr 2018 to 21 Dec 2018.